| Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript |
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joel Beatty - Baird Charles Duncan - Cantor Fitzgerald Rohan Matur - Oppenheimer & Co. Inc. Jason Gerberry - Bank of America Global Research Felix Ampomah - Stephens & Co. Operator Good day everyone, and welcome to the Catalyst Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-08 16:02:12 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y |
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales. |
zacks.com |
2025-05-08 16:00:50 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics |
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-08 00:05:52 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates |
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago. |
zacks.com |
2025-05-07 23:31:01 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update |
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 Million Strengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2025 and provided a business update. |
globenewswire.com |
2025-05-07 20:14:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? |
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:58 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 |
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. |
globenewswire.com |
2025-04-30 12:03:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 |
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET |
globenewswire.com |
2025-04-22 12:03:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals |
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE would be the first and only treatment option indicated for patients diagnosed with DMD in Canada. |
globenewswire.com |
2025-04-08 12:06:00 |
Czytaj oryginał (ang.) |
| Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday |
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared. |
fool.com |
2025-04-03 20:50:48 |
Czytaj oryginał (ang.) |
| Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? |
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-28 14:36:07 |
Czytaj oryginał (ang.) |
| Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win |
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily. |
investors.com |
2025-03-27 14:21:19 |
Czytaj oryginał (ang.) |
| Strong Revenue, Drug Performance Lift Catalyst Shares |
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX). |
fxempire.com |
2025-03-26 10:12:51 |
Czytaj oryginał (ang.) |
| Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? |
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-03-25 14:10:23 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts |
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offering an attractive asymmetric trade payoff with a potential 40% upside, despite risks associated with acquisition-dependent revenue growth. |
seekingalpha.com |
2025-03-11 06:05:33 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference |
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 being held in Miami, Florida. |
globenewswire.com |
2025-03-04 10:03:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges |
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “managed and gradual” revenue decline. |
seekingalpha.com |
2025-03-03 16:39:44 |
Czytaj oryginał (ang.) |
| Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today |
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected. |
fool.com |
2025-02-27 16:35:42 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript |
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joseph Catanzaro - Piper Sandler Joel Beatty - Baird Felix Ampomah - Stephens Operator Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-27 14:29:03 |
Czytaj oryginał (ang.) |
| CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up |
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. |
zacks.com |
2025-02-27 12:10:31 |
Czytaj oryginał (ang.) |
| Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-26 23:30:35 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates |
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. |
zacks.com |
2025-02-26 21:50:22 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2024 and provided a business update. |
globenewswire.com |
2025-02-26 18:13:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 |
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025. |
globenewswire.com |
2025-02-12 10:03:00 |
Czytaj oryginał (ang.) |
| Catalyst Remains a Big Money Favorite |
Catalyst Pharmaceuticals, Inc. (CPRX) shares keep gaining on Big Money buys. |
fxempire.com |
2025-02-07 17:56:43 |
Czytaj oryginał (ang.) |
| This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry |
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point. |
investors.com |
2025-01-31 10:00:30 |
Czytaj oryginał (ang.) |
| Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-24 12:55:24 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies |
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list. |
globenewswire.com |
2025-01-23 10:03:00 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2025-01-22 11:55:32 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan |
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS"). |
globenewswire.com |
2025-01-21 10:19:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE |
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver. |
seekingalpha.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva |
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035. |
zacks.com |
2025-01-09 12:56:21 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Catalyst (CPRX) Should Keep going |
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-01-09 12:01:51 |
Czytaj oryginał (ang.) |
| Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? |
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-09 11:20:23 |
Czytaj oryginał (ang.) |
| IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva |
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva appeared first on Investor's Business Daily. |
investors.com |
2025-01-08 16:57:04 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals |
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 |
globenewswire.com |
2025-01-08 14:30:00 |
Czytaj oryginał (ang.) |
| Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-07 13:06:41 |
Czytaj oryginał (ang.) |
| Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-24 12:51:11 |
Czytaj oryginał (ang.) |
| Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-18 12:40:28 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA. |
globenewswire.com |
2024-12-16 10:03:00 |
Czytaj oryginał (ang.) |
| Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report? |
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-09 08:49:27 |
Czytaj oryginał (ang.) |
| Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-02 17:26:24 |
Czytaj oryginał (ang.) |
| Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-27 13:01:14 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List |
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution |
globenewswire.com |
2024-11-25 10:03:00 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences |
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. |
globenewswire.com |
2024-11-19 10:03:00 |
Czytaj oryginał (ang.) |
| Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-15 12:51:44 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work |
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community. |
globenewswire.com |
2024-11-13 10:03:00 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance |
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article. |
zacks.com |
2024-11-11 10:51:11 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Trump Gets Re-Elected |
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio. |
zacks.com |
2024-11-08 10:21:31 |
Czytaj oryginał (ang.) |
| CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up |
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance. |
zacks.com |
2024-11-07 13:30:36 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript |
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Richard Daly - President and Chief Executive Officer Michael Kalb - Chief Financial Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical & Regulatory Officer Conference Call Participants Joon Lee - Truist Securities Charles Duncan - Cantor Fitzgerald Samantha Semenkow - Citi Investment Research Operator Thank you for standing by. My name is Kris and I will be your conference operator today. |
seekingalpha.com |
2024-11-07 12:34:10 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? |
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-07 12:20:36 |
Czytaj oryginał (ang.) |
| Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say |
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-06 21:00:31 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates |
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-11-06 20:26:19 |
Czytaj oryginał (ang.) |
| Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update |
Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase |
globenewswire.com |
2024-11-06 18:12:00 |
Czytaj oryginał (ang.) |
| CPRX vs. STVN: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-06 14:45:45 |
Czytaj oryginał (ang.) |
| Pick These 4 Solid Net Profit Margin Stocks to Boost Portfolio Return |
Pick these four top-ranked stocks, VRT, LMB, ATAT and CPRX, with solid net profit margins to enhance your portfolio returns. |
zacks.com |
2024-10-28 12:05:29 |
Czytaj oryginał (ang.) |